|
1
|
Bray F, Laversanne M, Sung H, Ferlay J,
Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics
2022: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 74:229–263.
2024.PubMed/NCBI
|
|
2
|
Liu Y, Fang C, Luo J, Gong C, Wang L and
Zhu S: Traditional Chinese medicine for cancer treatment. Am J Chin
Med. 52:583–604. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Li Y, Miao J, Liu C, Tao J, Zhou S, Song
X, Zou Y, Huang Y and Zhong L: Kushenol O Regulates GALNT7/NF-κB
axis-Mediated Macrophage M2 Polarization and Efferocytosis in
papillary thyroid carcinoma. Phytomedicine. 138:1563732025.
View Article : Google Scholar
|
|
4
|
Szopa A, Ekiert R and Ekiert H: Current
knowledge of Schisandra chinensis (Turcz.) Baill. (Chinese
magnolia vine) as a medicinal plant species: A review on the
bioactive components, pharmacological properties, analytical and
biotechnological studies. Phytochem Rev. 16:195–218. 2017.
|
|
5
|
Yang K, Qiu J, Huang Z, Yu Z, Wang W, Hu H
and You Y: A comprehensive review of ethnopharmacology,
phytochemistry, pharmacology, and pharmacokinetics of Schisandra
chinensis (Turcz.) Baill. and Schisandra sphenanthera Rehd. et
Wils. J Ethnopharmacol. 284:1147592022. View Article : Google Scholar
|
|
6
|
Olas B: Cardioprotective potential of
berries of Schisandra chinensis Turcz. (Baill.), their components
and food products. Nutrients. 15:5922023. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shan Y, Jiang B, Yu J, Wang J, Wang X, Li
H, Wang C, Chen J and Sun J: Protective Effect of Schisandra
chinensis polysaccharides against the immunological liver injury in
mice based on Nrf2/ARE and TLR4/NF-κB signaling pathway. J Med
Food. 22:885–895. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yan T, Mao Q, Zhang X, Wu B, Bi K, He B
and Jia Y: Schisandra chinensis protects against dopaminergic
neuronal oxidative stress, neuroinflammation and apoptosis via the
BDNF/Nrf2/NF-κB pathway in 6-OHDA-induced Parkinson's disease mice.
Food Funct. 12:4079–4091. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Xu G, Lv X, Feng Y, Li H, Chen C, Lin H,
Li H, Wang C, Chen J and Sun J: Study on the effect of active
components of Schisandra chinensis on liver injury and its
mechanisms in mice based on network pharmacology. Eur J Pharmacol.
910:1744422021. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yuan R, Tao X, Liang S, Pan Y, He L, Sun
J, Wenbo J, Li X, Chen J and Wang C: Protective effect of acidic
polysaccharide from Schisandra chinensis on acute ethanol-induced
liver injury through reducing CYP2E1-dependent oxidative stress.
Biomed Pharmacother. 99:537–542. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang M, Xu L and Yang H: Schisandra
chinensis Fructus and its active ingredients as promising resources
for the treatment of neurological diseases. Int J Mol Sci.
19:19702018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Qiu Q, Zhang W, Liu K, Huang F, Su J, Deng
L, He J, Lin Q and Luo L: Schisandrin A ameliorates airway
inflammation in model of asthma by attenuating Th2 response. Eur J
Pharmacol. 953:1758502023. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lee K, Ahn JH, Lee KT, Jang DS and Choi
JH: Deoxyschizandrin, Isolated from Schisandra berries, induces
cell cycle arrest in ovarian cancer cells and inhibits the
protumoural activation of tumour-associated macrophages. Nutrients.
10:912018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lee PK, Co VA, Yang Y, Wan MLY, El-Nezami
H and Zhao D: Bioavailability and interactions of schisandrin B
with 5-fluorouracil in a xenograft mouse model of colorectal
cancer. Food Chem. 463:1413712025. View Article : Google Scholar
|
|
15
|
Nasser MI, Han T, Adlat S, Tian Y and
Jiang N: Inhibitory effects of Schisandrin B on human prostate
cancer cells. Oncol Rep. 41:677–685. 2019.
|
|
16
|
Sowndhararajan K, Deepa P, Kim M, Park SJ
and Kim S: An overview of neuroprotective and cognitive enhancement
properties of lignans from Schisandra chinensis. Biomed
Pharmacother. 97:958–968. 2018. View Article : Google Scholar
|
|
17
|
Tan S, Zheng Z, Liu T, Yao X, Yu M and Ji
Y: Schisandrin B induced ROS-mediated autophagy and Th1/Th2
imbalance via selenoproteins in Hepa1-6 cells. Front Immunol.
13:8570692022. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhan SY, Shao Q, Fan XH, Li Z and Cheng
YY: Tissue distribution and excretion of herbal components after
intravenous administration of a Chinese medicine (Shengmai
injection) in rat. Arch Pharm Res. Apr 19–2014.Epub ahead of print.
View Article : Google Scholar : PubMed/NCBI
Guo J, Shen Y, Lin X, Chen H and Liu J:
Schisandrin B promotes T(H)1 cell differentiation by targeting
STAT1. Int Immunopharmacol. 101:1082132021. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nasser MI, Zhu S, Chen C, Zhao M, Huang H
and Zhu P: A comprehensive review on Schisandrin B and its
biological properties. Oxid Med Cell Longev. 2020:21727402020.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chen Z, Guo M, Song G, Gao J, Zhang Y,
Jing Z, Liu T and Dong C: Schisandrin B inhibits Th1/Th17
differentiation and promotes regulatory T cell expansion in mouse
lymphocytes. Int Immunopharmacol. 35:257–264. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kortesoja M, Karhu E, Olafsdottir ES,
Freysdottir J and Hanski L: Impact of dibenzocyclooctadiene lignans
from Schisandra chinensis on the redox status and activation of
human innate immune system cells. Free Radic Biol Med. 131:309–317.
2019. View Article : Google Scholar
|
|
22
|
Chang CM, Liang TR and Lam HYP: The use of
Schisandrin B to combat Triple-negative breast cancers by
inhibiting NLRP3-Induced interleukin-1β production. Biomolecules.
14:742024. View Article : Google Scholar
|
|
23
|
Song A, Ding T, Wei N, Yang J, Ma M, Zheng
S and Jin H: Schisandrin B induces HepG2 cells pyroptosis by
activating NK cells mediated anti-tumor immunity. Toxicol Appl
Pharmacol. 472:1165742023. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xie Z, Yang T, Zhou C, Xue Z, Wang J and
Lu F: Integrative bioinformatics analysis and experimental study of
NLRP12 reveal its prognostic value and potential functions in
ovarian cancer. Mol Carcinog. 64:383–398. 2025. View Article : Google Scholar
|
|
25
|
Chen X, Liu C, Deng J, Xia T, Zhang X, Xue
S, Song MK and Olatunji OJ: Schisandrin B ameliorates
adjuvant-induced arthritis in rats via modulation of inflammatory
mediators, oxidative stress, and HIF-1α/VEGF pathway. J Pharm
Pharmacol. 76:681–690. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang L, Chen H, Tian J and Chen S:
Antioxidant and anti-proliferative activities of five compounds
from Schisandra chinensis fruit. Industrial Crops Products.
50:690–693. 2013. View Article : Google Scholar
|
|
27
|
Chen T, Xiao Z, Liu X, Wang T, Wang Y, Ye
F, Su J, Yao X, Xiong L and Yang DH: Natural products for combating
multidrug resistance in cancer. Pharmacol Res. 202:1070992024.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Krishnan SR and Bebawy M: Circulating
biosignatures in multiple myeloma and their role in multidrug
resistance. Mol Cancer. 22:792023. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li Z and Yin P: Tumor microenvironment
diversity and plasticity in cancer multidrug resistance. Biochim
Biophys Acta Rev Cancer. 1878:1889972023. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chen YC, Malfertheiner P, Yu HT, Kuo CL,
Chang YY, Meng FT, Wu YX, Hsiao JL, Chen MJ, Lin KP, et al: Global
prevalence of helicobacter pylori infection and incidence of
gastric cancer between 1980 and 2022. Gastroenterology.
166:605–619. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yuan J, Khan SU, Yan J, Lu J, Yang C and
Tong Q: Baicalin enhances the efficacy of 5-Fluorouracil in gastric
cancer by promoting ROS-mediated ferroptosis. Biomed Pharmacother.
164:1149862023. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
He L, Chen H, Qi Q, Wu N, Wang Y, Chen M,
Feng Q, Dong B, Jin R and Jiang L: Schisandrin B suppresses gastric
cancer cell growth and enhances the efficacy of chemotherapy drug
5-FU in vitro and in vivo. Eur J Pharmacol. 920:1748232022.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhang F, Wang Z, Yuan J, Wei X, Tian R and
Niu R: RNAi-mediated silencing of Anxa2 inhibits breast cancer cell
proliferation by downregulating cyclin D1 in STAT3-dependent
pathway. Breast Cancer Res Treat. 153:263–275. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liu XN, Zhang CY, Jin XD, Li YZ, Zheng XZ
and Li L: Inhibitory effect of schisandrin B on gastric cancer
cells in vitro. World J Gastroenterol. 13:6506–6511. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Li M, Tang Q, Li S, Yang X, Zhang Y, Tang
X, Huang P and Yin D: Inhibition of autophagy enhances the
anticancer effect of Schisandrin B on head and neck squamous cell
carcinoma. J Biochem Mol Toxicol. 38:e235852024. View Article : Google Scholar
|
|
36
|
Zhang F, Zhai J, Weng N, Gao J, Yin J and
Chen W: A comprehensive review of the main lignan components of
Schisandra chinensis (North Wu Wei Zi) and Schisandra
sphenanthera (South Wu Wei Zi) and the Lignan-induced drug-drug
interactions based on the inhibition of cytochrome P450 and
P-glycoprotein activities. Front Pharmacol. 13:8160362022.
|
|
37
|
Morgan E, Arnold M, Gini A, Lorenzoni V,
Cabasag CJ, Laversanne M, Vignat J, Ferlay J, Murphy N and Bray F:
Global burden of colorectal cancer in 2020 and 2040: Incidence and
mortality estimates from GLOBOCAN. Gut. 72:338–344. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Vodenkova S, Buchler T, Cervena K,
Veskrnova V, Vodicka P and Vymetalkova V: 5-fluorouracil and other
fluoropyrimidines in colorectal cancer: Past, present and future.
Pharmacol Ther. 206:1074472020. View Article : Google Scholar
|
|
39
|
Yoshino T, Cervantes A, Bando H,
Martinelli E, Oki E, Xu RH, Mulansari NA, Govind Babu K, Lee MA and
Tan CK: Pan-Asian adapted ESMO Clinical Practice Guidelines for the
diagnosis, treatment and follow-up of patients with metastatic
colorectal cancer. ESMO Open. 8:1015582023. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Co VA, El-Nezami H, Liu Y, Twum B, Dey P,
Cox PA, Joseph S, Agbodjan-Dossou R, Sabzichi M, Draheim R and Wan
MLY: Schisandrin B suppresses colon cancer growth by inducing cell
cycle arrest and apoptosis: Molecular mechanism and therapeutic
potential. ACS Pharmacol Transl Sci. 7:863–877. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Pu Z, Zhang W, Wang M, Xu M, Xie H and
Zhao J: Schisandrin B attenuates Colitis-associated colorectal
cancer through SIRT1 linked SMURF2 signaling. Am J Chin Med.
49:1773–1789. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Cheifetz S, Hernandez H, Laiho M, ten
Dijke P, Iwata KK and Massagué J: Distinct transforming growth
factor-beta (TGF-beta) receptor subsets as determinants of cellular
responsiveness to three TGF-beta isoforms. J Biol Chem.
265:20533–20538. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Dong X, Zhao B, Iacob RE, Zhu J, Koksal
AC, Lu C, Engen JR and Springer TA: Force interacts with
macromolecular structure in activation of TGF-β. Nature. 542:55–59.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Lamouille S, Xu J and Derynck R: Molecular
mechanisms of Epithelial-mesenchymal transition. Nat Rev Mol Cell
Biol. 15:178–196. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Vincent T, Neve EP, Johnson JR, Kukalev A,
Rojo F, Albanell J, Pietras K, Virtanen I, Philipson L, Leopold PL,
et al: A SNAIL1-SMAD3/4 transcriptional repressor complex promotes
TGF-beta mediated epithelial-mesenchymal transition. Nat Cell Biol.
11:943–950. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Xue G, Restuccia DF, Lan Q, Hynx D,
Dirnhofer S, Hess D, Rüegg C and Hemmings BA: Akt/PKB-mediated
phosphorylation of Twist1 promotes tumor metastasis via mediating
cross-talk between PI3K/Akt and TGF-β signaling axes. Cancer
Discov. 2:248–259. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Lin T, Zeng L, Liu Y, DeFea K, Schwartz
MA, Chien S and Shyy JY: Rho-ROCK-LIMK-cofilin pathway regulates
shear stress activation of sterol regulatory element binding
proteins. Circ Res. 92:1296–1304. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Yu J, Lei R, Zhuang X, Li X, Li G, Lev S,
Segura MF, Zhang X and Hu G: MicroRNA-182 targets SMAD7 to
potentiate TGFβ-induced epithelial-mesenchymal transition and
metastasis of cancer cells. Nat Commun. 7:138842016. View Article : Google Scholar
|
|
49
|
Tian XJ, Zhang H and Xing J: Coupled
reversible and irreversible bistable switches underlying
TGFβ-induced epithelial to mesenchymal transition. Biophys J.
105:1079–1089. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Liu Z, Zhang B, Liu K, Ding Z and Hu X:
Schisandrin B attenuates cancer invasion and metastasis via
inhibiting epithelial-mesenchymal transition. PLoS One.
7:e404802012. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Zhang B, Liu Z and Hu X: Inhibiting cancer
metastasis via targeting NAPDH oxidase 4. Biochem Pharmacol.
86:253–266. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Li J, Lu Y, Wang D, Quan F, Chen X, Sun R,
Zhao S, Yang Z, Tao W, Ding D, et al: Schisandrin B prevents
ulcerative colitis and colitis-associated-cancer by activating
focal adhesion kinase and influence on gut microbiota in an in vivo
and in vitro model. Eur J Pharmacol. 854:9–21. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Sun R, Zhang Y, Zhao X, Tang T, Cao Y,
Yang L, Tian Y, Zhang Z, Zhang P and Xu F: Temporal and spatial
metabolic shifts revealing the transition from ulcerative colitis
to colitis-associated colorectal cancer. Adv Sci (Weinh).
12:e24125512025. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Zhang J, Mengli Y, Zhang T, Song X, Ying
S, Shen Z and Yu C: Deficiency in epithelium RAD50 aggravates UC
via IL-6-Mediated JAK1/2-STAT3 signaling and promotes development
of Colitis-associated cancer in mice. J Crohns Colitis.
19:jjae1342025. View Article : Google Scholar
|
|
55
|
Porter RJ, Kalla R and Ho GT: Ulcerative
colitis: Recent advances in the understanding of disease
pathogenesis. F1000Res. 9:F1000Faculty Rev-294. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Tatiya-Aphiradee N, Chatuphonprasert W and
Jarukamjorn K: Immune response and inflammatory pathway of
ulcerative colitis. J Basic Clin Physiol Pharmacol. 30:1–10. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Guo G, Tan Z, Liu Y, Shi F and She J: The
therapeutic potential of stem Cell-derived exosomes in the
ulcerative colitis and colorectal cancer. Stem Cell Res Ther.
13:1382022. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Guo X, Yin X, Liu Z and Wang J:
Non-alcoholic fatty liver disease (NAFLD) pathogenesis and natural
products for prevention and treatment. Int J Mol Sci. 23:154892022.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Asaoka Y, Terai S, Sakaida I and Nishina
H: The expanding role of fish models in understanding non-alcoholic
fatty liver disease. Dis Model Mech. 6:905–914. 2013.PubMed/NCBI
|
|
60
|
Sheka AC, Adeyi O, Thompson J, Hameed B,
Crawford PA and Ikramuddin S: Nonalcoholic steatohepatitis: A
review. JAMA. 323:1175–1183. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Leong PK and Ko KM: Schisandrin B: A
Double-edged sword in nonalcoholic fatty liver disease. Oxid Med
Cell Longev. 2016:61716582016. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Yan LS, Zhang SF, Luo G, Cheng BC, Zhang
C, Wang YW, Qiu XY, Zhou XH, Wang QG, Song XL, et al: Schisandrin B
mitigates hepatic steatosis and promotes fatty acid oxidation by
inducing autophagy through AMPK/mTOR signaling pathway. Metabolism.
131:1552002022. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Ma R, Zhan Y, Zhang Y, Wu L, Wang X and
Guo M: Schisandrin B ameliorates non-alcoholic liver disease
through anti-inflammation activation in diabetic mice. Drug Dev
Res. 83:735–744. 2022.
|
|
64
|
Li Z, Zhao L, Xia Y, Chen J, Hua M and Sun
Y: Schisandrin B attenuates hepatic stellate cell activation and
promotes apoptosis to protect against liver fibrosis. Molecules.
26:68822021. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Ma M, Wei N, Yang J, Ding T, Song A, Chen
L, Zheng S and Jin H: Schisandrin B promotes senescence of
activated hepatic stellate cell via NCOA4-mediated ferritinophagy.
Pharm Biol. 61:621–629. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Trojnar E, Erdelyi K, Matyas C, Zhao S,
Paloczi J, Mukhopadhyay P, Varga ZV, Hasko G and Pacher P:
Cannabinoid-2 receptor activation ameliorates hepatorenal syndrome.
Free Radic Biol Med. 152:540–550. 2020. View Article : Google Scholar
|
|
67
|
Wang HQ, Wan Z, Zhang Q, Su T, Yu D, Wang
F, Zhang C, Li W, Xu D and Zhang H: Schisandrin B targets
cannabinoid 2 receptor in Kupffer cell to ameliorate CCl4-induced
liver fibrosis by suppressing NF-κB and p38 MAPK pathway.
Phytomedicine. 98:1539602022. View Article : Google Scholar
|
|
68
|
Yang YY, Hsieh SL, Lee PC, Yeh YC, Lee KC,
Hsieh YC, Wang YW, Lee TY, Huang YH, Chan CC and Lin HC: Long-term
cannabinoid type 2 receptor agonist therapy decreases bacterial
translocation in rats with cirrhosis and ascites. J Hepatol.
61:1004–1013. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Lei Y, Wang QL, Shen L, Tao YY and Liu CH:
MicroRNA-101 suppresses liver fibrosis by downregulating
PI3K/Akt/mTOR signaling pathway. Clin Res Hepatol Gastroenterol.
43:575–584. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Cuiqiong W, Chao X, Xinling F and Yinyan
J: Schisandrin B suppresses liver fibrosis in rats by targeting
miR-101-5p through the TGF-β signaling pathway. Artif Cells Nanomed
Biotechnol. 48:473–478. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Meroni M, Longo M, Erconi V, Valenti L,
Gatti S, Fracanzani AL and Dongiovanni P: mir-101-3p downregulation
promotes fibrogenesis by facilitating hepatic stellate cell
transdifferentiation during insulin resistance. Nutrients.
11:25972019. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Chen Q, Bao L, Lv L, Xie F, Zhou X, Zhang
H and Zhang G: Schisandrin B regulates macrophage polarization and
alleviates liver fibrosis via activation of PPARγ. Ann Transl Med.
9:15002021. View Article : Google Scholar
|
|
73
|
Leong PK, Wong HS, Chen J, Chan WM, Leung
HY and Ko KM: Differential Action between Schisandrin A and
Schisandrin B in eliciting an Anti-inflammatory Action: The
depletion of reduced glutathione and the induction of an
antioxidant response. PLoS One. 11:e01558792016. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Ma Z, Xu G, Shen Y, Hu S, Lin X, Zhou J,
Zhao W, Liu J, Wang J and Guo J: Schisandrin B-mediated TH17 cell
differentiation attenuates bowel inflammation. Pharmacol Res.
166:1054592021. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Chen Q, Zhang H, Cao Y, Li Y, Sun S, Zhang
J and Zhang G: Schisandrin B attenuates CCl4-induced liver fibrosis
in rats by regulation of Nrf2-ARE and TGF-β/Smad signaling
pathways. Drug Des Devel Ther. 11:2179–2191. 2017. View Article : Google Scholar :
|
|
76
|
Jin M, Yi X, Zhu X, Hu W, Wang S, Chen Q,
Yang W, Li Y, Li S, Peng Q, et al: Schisandrin B promotes hepatic
differentiation from human umbilical cord mesenchymal stem cells.
iScience. 27:1089122024. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Anwanwan D, Singh SK, Singh S, Saikam V
and Singh R: Challenges in liver cancer and possible treatment
approaches. Biochim Biophys Acta Rev Cancer. 1873:1883142020.
View Article : Google Scholar :
|
|
78
|
Yang H and Wu T: Schisandrin B inhibits
tumor progression of hepatocellular carcinoma by targeting the
RhoA/ROCK1 pathway. J Gastrointest Oncol. 14:533–543. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Zhang JG, Zhou HM, Zhang X, Mu W, Hu JN,
Liu GL and Li Q: Hypoxic induction of vasculogenic mimicry in
hepatocellular carcinoma: Role of HIF-1 α, RhoA/ROCK and Rac1/PAK
signaling. BMC Cancer. 20:322020. View Article : Google Scholar
|
|
80
|
He JL, Zhou ZW, Yin JJ, He CQ, Zhou SF and
Yu Y: Schisandra chinensis regulates drug metabolizing enzymes and
drug transporters via activation of Nrf2-mediated signaling
pathway. Drug Des Devel Ther. 9:127–146. 2015.PubMed/NCBI
|
|
81
|
Benson AB, D'Angelica MI, Abrams T, Abbott
DE, Ahmed A, Anaya DA, Anders R, Are C, Bachini M, Binder D, et al:
NCCN Guidelines® Insights: Biliary tract cancers,
version 2.2023. J Natl Compr Canc Netw. 21:694–704. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Sarcognato S, Sacchi D, Fassan M, Fabris
L, Cadamuro M, Zanus G, Cataldo I, Capelli P, Baciorri F,
Cacciatore M and Guido M: Cholangiocarcinoma. Pathologica.
113:158–169. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Yang X, Wang S, Mu Y and Zheng Y:
Schisandrin B inhibits cell proliferation and induces apoptosis in
human cholangiocarcinoma cells. Oncol Rep. 36:1799–1806. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Pehlivanoglu B, Akkas G, Memis B, Basturk
O, Reid MD, Saka B, Dursun N, Bagci P, Balci S, Sarmiento J, et al:
Reappraisal of T1b gallbladder cancer (GBC): Clinicopathologic
analysis of 473 in situ and invasive GBCs and critical review of
the literature highlights its rarity, and that it has a very good
prognosis. Virchows Arch. 482:311–323. 2023. View Article : Google Scholar
|
|
85
|
Brindley PJ, Bachini M, Ilyas SI, Khan SA,
Loukas A, Sirica AE, The BT, Wongkham S and Gores GJ:
Cholangiocarcinoma. Nat Rev Dis Primers. 7:652021. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Hui AM, Li X, Shi YZ, Takayama T, Torzilli
G and Makuuchi M: Cyclin D1 overexpression is a critical event in
gallbladder carcinogenesis and independently predicts decreased
survival for patients with gallbladder carcinoma. Clin Cancer Res.
6:4272–4277. 2000.PubMed/NCBI
|
|
87
|
Cai Z, Wang J, Li Y, Shi Q, Jin L, Li S,
Zhu M, Wang Q, Wong LL, Yang W, et al: Overexpressed Cyclin D1 and
CDK4 proteins are responsible for the resistance to CDK4/6
inhibitor in breast cancer that can be reversed by PI3K/mTOR
inhibitors. Sci China Life Sci. 66:94–109. 2023. View Article : Google Scholar
|
|
88
|
Vogel A, Segatto O, Stenzinger A and
Saborowski A: FGFR2 Inhibition in Cholangiocarcinoma. Annu Rev Med.
74:293–306. 2023. View Article : Google Scholar
|
|
89
|
Banik K, Khatoon E, Harsha C, Rana V,
Parama D, Thakur KK, Bishayee A and Kunnumakkara AB: Wogonin and
its analogs for the prevention and treatment of cancer: A
systematic review. Phytother Res. 36:1854–1883. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Zhao C, Zhang J, Yang ZY, Shi LQ, Liu SL,
Pan LJ, Dong P, Zhang Y, Xiang SS, Shu YJ and Mei JW: Ponicidin
inhibited gallbladder cancer proliferation and metastasis by
decreasing MAGEB2 expression through FOXO4. Phytomedicine.
114:1547852023. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Tsang CM, Lui VWY, Bruce JP, Pugh TJ and
Lo KW: Translational genomics of nasopharyngeal cancer. Semin
Cancer Biol. 61:84–100. 2020. View Article : Google Scholar
|
|
92
|
Pan JJ, Ng WT, Zong JF, Chan LL,
O'Sullivan B, Lin SJ, Sze HC, Chen YB, Choi HC, Guo QJ, et al:
Proposal for the 8th edition of the AJCC/UICC staging system for
nasopharyngeal cancer in the era of intensity-modulated
radiotherapy. Cancer. 122:546–558. 2016. View Article : Google Scholar
|
|
93
|
Hong S, Zhang Y, Yu G, Peng P, Peng J, Jia
J, Wu X, Huang Y, Yang Y, Lin Q, et al: Gemcitabine plus cisplatin
versus fluorouracil plus cisplatin as First-Line therapy for
recurrent or metastatic nasopharyngeal carcinoma: Final overall
survival analysis of GEM20110714 Phase III study. J Clin Oncol.
39:3273–3282. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Fang Y, Lv X, Li G, Wang P, Zhang L, Wang
R, Jia L and Liang S: Schisandrin B targets CDK4/6 to suppress
proliferation and enhance radiosensitivity in nasopharyngeal
carcinoma by inducing cell cycle arrest. Sci Rep. 15:84522025.
View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Lv XJ, Zhao LJ, Hao YQ, Su ZZ, Li JY, Du
YW and Zhang J: Schisandrin B inhibits the proliferation of human
lung adenocarcinoma A549 cells by inducing cycle arrest and
apoptosis. Int J Clin Exp Med. 8:6926–6936. 2015.PubMed/NCBI
|
|
96
|
Xiang SS, Wang XA, Li HF, Shu YJ, Bao RF,
Zhang F, Cao Y, Ye YY, Weng H, Wu WG, et al: Schisandrin B induces
apoptosis and cell cycle arrest of gallbladder cancer cells.
Molecules. 19:13235–13250. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Xie X, Zheng W, Chen T, Lin W, Liao Z, Liu
J and Ding Y: CDK4/6 inhibitor palbociclib amplifies the
radiosensitivity to nasopharyngeal carcinoma cells via mediating
apoptosis and suppressing DNA damage repair. Onco Targets Ther.
12:11107–11117. 2019. View Article : Google Scholar
|
|
98
|
Luo W, Lin K, Hua J, Han J, Zhang Q, Chen
L, Khan ZA, Wu G, Wang Y and Liang G: Schisandrin B attenuates
diabetic cardiomyopathy by targeting MyD88 and inhibiting
MyD88-Dependent inflammation. Adv Sci (Weinh). 9:e22025902022.
View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Xu C, Deng Y, Man J, Wang H, Che T, Ding L
and Yang L: Unveiling the renoprotective mechanisms of Schisandrin
B in ischemia-reperfusion injury through transcriptomic and
pharmacological analysis. Drug Des Devel Ther. 18:4241–4256. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Huang W, Zhang L, Yang M, Wu X, Wang X,
Huang W, Yuan L, Pan H, Wang Y and Wang Z: Cancer-associated
fibroblasts promote the survival of irradiated nasopharyngeal
carcinoma cells via the NF-κB pathway. J Exp Clin Cancer Res.
40:872021. View Article : Google Scholar
|
|
101
|
Nishida H, Tatewaki N, Nakajima Y, Magara
T, Ko KM, Hamamori Y and Konishi T: Inhibition of ATR protein
kinase activity by schisandrin B in DNA damage response. Nucleic
Acids Res. 37:5678–5689. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Meyer ML, Fitzgerald BG, Paz-Ares L,
Cappuzzo F, Jänne PA, Peters S and Hirsch FR: New promises and
challenges in the treatment of advanced non-small-cell lung cancer.
Lancet. 404:803–822. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Zhuang W, Li Z, Dong X, Zhao N, Liu Y,
Wang C and Chen J: Schisandrin B inhibits TGF-β1-induced
epithelial-mesenchymal transition in human A549 cells through
epigenetic silencing of ZEB1. Exp Lung Res. 45:157–166. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Desai K, McManus JM and Sharifi N:
Hormonal therapy for prostate cancer. Endocr Rev. 42:354–373. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Ho Y and Dehm SM: Androgen receptor
rearrangement and splicing variants in resistance to endocrine
therapies in prostate cancer. Endocrinology. 158:1533–1542. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Dai C, Heemers H and Sharifi N: Androgen
signaling in prostate cancer. Cold Spring Harb Perspect Med.
7:a0304522017. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Zhang BY, Yang R, Zhu WQ, Zhu CL, Chen LX,
Zhao YS, Zhang Y, Wang YQ, Jiang DZ and Tang B: Schisandrin B
alleviates testicular inflammation and Sertoli cell apoptosis via
AR-JNK pathway. Sci Rep. 14:184182024. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Zhang Q, Liu J, Duan H, Li R, Peng W and
Wu C: Activation of Nrf2/HO-1 signaling: An important molecular
mechanism of herbal medicine in the treatment of atherosclerosis
via the protection of vascular endothelial cells from oxidative
stress. J Adv Res. 34:43–63. 2021. View Article : Google Scholar
|
|
109
|
Zafar MK and Eoff RL: Translesion DNA
synthesis in cancer: Molecular mechanisms and therapeutic
opportunities. Chem Res Toxicol. 30:1942–1955. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Wu Y, Li ZC, Yao LQ, Li M and Tang M:
Schisandrin B alleviates acute oxidative stress via modulation of
the Nrf2/Keap1-mediated antioxidant pathway. Appl Physiol Nutr
Metab. 44:1–6. 2019. View Article : Google Scholar
|
|
111
|
Ostrom QT, Price M, Neff C, Cioffi G,
Waite KA, Kruchko C and Barnholtz-Sloan JS: CBTRUS statistical
report: Primary brain and other central nervous system tumors
diagnosed in the united states in 2015-2019. Neuro Oncol.
24:v1–v95. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Qi L, Yu HQ, Li YQ, Jin H, Zhao DH and Xu
Y: Schidandrin B kills tumor cells by initiating apoptosis in
glioma SHG-44 cells. Chin J Integr Med. Aug 2–2016.Epub ahead of
print. View Article : Google Scholar
|
|
113
|
Li Q, Lu XH, Wang CD, Cai L, Lu JL, Wu JS,
Zhuge QC, Zheng WM and Su ZP: Antiproliferative and
apoptosis-inducing activity of schisandrin B against human glioma
cells. Cancer Cell Int. 15:122015. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Jiang Y, Zhang Q, Bao J, Du C, Wang J,
Tong Q and Liu C: Schisandrin B suppresses glioma cell metastasis
mediated by inhibition of mTOR/MMP-9 signal pathway. Biomed
Pharmacother. 74:77–82. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Zhang Z, Wang Y, Chen J, Tan Q, Xie C, Li
C, Zhan W and Wang M: Silencing of histone deacetylase 2 suppresses
malignancy for proliferation, migration, and invasion of
glioblastoma cells and enhances temozolomide sensitivity. Cancer
Chemother Pharmacol. 78:1289–1296. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Tomar MS, Kumar A, Srivastava C and
Shrivastava A: Elucidating the mechanisms of Temozolomide
resistance in gliomas and the strategies to overcome the
resistance. Biochim Biophys Acta Rev Cancer. 1876:1886162021.
View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Jiang Y, Zhang Q, Bao J, Du C, Wang J,
Tong Q and Liu C: Schisandrin B inhibits the proliferation and
invasion of glioma cells by regulating the HOTAIR-micoRNA-125a-mTOR
pathway. Neuroreport. 28:93–100. 2017. View Article : Google Scholar
|
|
118
|
Kostka L, Sivák L, Šubr V, Kovářová J,
Šírová M, Říhová B, Sedlacek R, Etrych T and Kovář M: Simultaneous
delivery of doxorubicin and protease inhibitor derivative to solid
tumors via Star-shaped polymer nanomedicines overcomes P-gp- and
STat3-mediated chemoresistance. Biomacromolecules. 23:2522–2535.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Chen XY, Wu ZX, Wang JQ, Teng QX, Tang H,
Liu Q, Chen ZS and Chen W: Multidrug resistance transporters P-gp
and BCRP limit the efficacy of ATR inhibitor ceralasertib in cancer
cells. Front Pharmacol. 15:14006992024. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Rebbaa A, Chou PM and Mirkin BL: Factors
secreted by human neuroblastoma mediated doxorubicin resistance by
activating STAT3 and inhibiting apoptosis. Mol Med. 7:393–400.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Wang S, Wang A, Shao M, Lin L, Li P and
Wang Y: Schisandrin B reverses doxorubicin resistance through
inhibiting P-glycoprotein and promoting proteasome-mediated
degradation of survivin. Sci Rep. 7:84192017. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Boudreau HE, Casterline BW, Rada B,
Korzeniowska A and Leto TL: Nox4 involvement in TGF-beta and
SMAD3-driven induction of the epithelial-to-mesenchymal transition
and migration of breast epithelial cells. Free Radic Biol Med.
53:1489–1499. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Dai X, Yin C, Guo G, Zhang Y, Zhao C, Qian
J, Wang O, Zhang X and Liang G: Schisandrin B exhibits potent
anticancer activity in triple negative breast cancer by inhibiting
STAT3. Toxicol Appl Pharmacol. 358:110–119. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Beird HC, Bielack SS, Flanagan AM, Gill J,
Heymann D, Janeway KA, Livingston JA, Roberts RD, Strauss SJ and
Gorlick R: Osteosarcoma. Nat Rev Dis Primers. 8:772022. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Sayles LC, Breese MR, Koehne AL, Leung SG,
Lee AG, Liu HY, Spillinger A, Shah AT, Tanasa B, Straessler K, et
al: Genome-informed targeted therapy for osteosarcoma. Cancer
Discov. 9:46–63. 2019. View Article : Google Scholar
|
|
126
|
Bacci G, Rocca M, Salone M, Balladelli A,
Ferrari S, Palmerini E, Forni C and Briccoli A: High grade
osteosarcoma of the extremities with lung metastases at
presentation: Treatment with neoadjuvant chemotherapy and
simultaneous resection of primary and metastatic lesions. J Surg
Oncol. 98:415–420. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Zhu KP, Zhang CL, Ma XL, Hu JP, Cai T and
Zhang L: Analyzing the interactions of mRNAs and ncRNAs to predict
competing endogenous RNA networks in osteosarcoma Chemo-resistance.
Mol Ther. 27:518–530. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Wang B, Wang X, Tong X and Zhang Y:
Schisandrin B inhibits cell viability and migration, and induces
cell apoptosis by circ_0009112/miR-708-5p axis through PI3K/AKT
pathway in osteosarcoma. Front Genet. 11:5886702020. View Article : Google Scholar
|
|
129
|
Thandavarayan RA, Giridharan VV, Arumugam
S, Suzuki K, Ko KM, Krishnamurthy P, Watanabe K and Konishi T:
Schisandrin B prevents doxorubicin induced cardiac dysfunction by
modulation of DNA damage, oxidative stress and inflammation through
inhibition of MAPK/p53 signaling. PLoS One. 10:e01192142015.
View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Li L, Pan Q, Han W, Liu Z, Li L and Hu X:
Schisandrin B prevents doxorubicin-induced cardiotoxicity via
enhancing glutathione redox cycling. Clin Cancer Res. 13:6753–6760.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Early Breast Cancer Trialists'
Collaborative Group (EBCTCG); Davies C, Godwin J, Gray R, Clarke M,
Cutter D, Darby S, McGale P, Pan HC, Taylor C, et al: Relevance of
breast cancer hormone receptors and other factors to the efficacy
of adjuvant tamoxifen: Patient-level meta-analysis of randomised
trials. Lancet. 378:771–784. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Li Y, Liu Z, Chen J, Wang R, An X, Tian C,
Yang H and Zha D: Schisandrin B protect inner hair cells from
cisplatin by inhibiting celluar oxidative stress and apoptosis.
Toxicol In Vitro. 99:1058522024. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Mei H, Zhao L, Li W, Zheng Z, Tang D, Lu X
and He Y: Inhibition of ferroptosis protects House Ear
Institute-Organ of Corti 1 cells and cochlear hair cells from
cisplatin-induced ototoxicity. J Cell Mol Med. 24:12065–12081.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Santos N, Ferreira RS and Santos ACD:
Overview of Cisplatin-induced neurotoxicity and ototoxicity, and
the protective agents. Food Chem Toxicol. 136:1110792020.
View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Shi H, Yan Y, Yang H, Pu P and Tang H:
Schisandrin B diet inhibits oxidative stress to reduce ferroptosis
and lipid peroxidation to prevent Pirarubicin-induced
hepatotoxicity. Biomed Res Int. 2022:56235552022. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Shi H, Tang H, Ai W, Zeng Q, Yang H, Zhu
F, Wei Y, Feng R, Wen L, Pu P and He Q: Schisandrin B antagonizes
cardiotoxicity induced by pirarubicin by inhibiting mitochondrial
permeability transition pore (mPTP) opening and decreasing
cardiomyocyte apoptosis. Front Pharmacol. 12:7338052021. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Tang H, Zhao J, Feng R, Pu P and Wen L:
Reducing oxidative stress may be important for treating
pirarubicin-induced cardiotoxicity with schisandrin B. Exp Ther
Med. 23:682022. View Article : Google Scholar
|
|
138
|
Zhang D, Liu B, Cao B, Wei F, Yu X, Li GF,
Chen H, Wei LQ and Wang PL: Synergistic protection of Schizandrin B
and Glycyrrhizic acid against bleomycin-induced pulmonary fibrosis
by inhibiting TGF-β1/Smad2 pathways and overexpression of NOX4. Int
Immunopharmacol. 48:67–75. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Lai Q, Luo Z, Wu C, Lai S, Wei H, Li T,
Wang Q and Yu Y: Attenuation of cyclosporine A induced
nephrotoxicity by schisandrin B through suppression of oxidative
stress, apoptosis and autophagy. Int Immunopharmacol. 52:15–23.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Lam HYP, Cheng PC and Peng SY: Resolution
of systemic complications in Schistosoma mansoni-infected mice by
concomitant treatment with praziquantel and Schisandrin B. Int J
Parasitol. 52:275–284. 2022. View Article : Google Scholar
|
|
141
|
Lam HYP, Liang TR and Peng SY:
Ameliorative effects of Schisandrin B on Schistosoma
Mansoni-induced hepatic fibrosis in vivo. PLoS Negl Trop Dis.
15:e00095542021. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Yan C, Gao L, Qiu X and Deng C:
Schisandrin B synergizes docetaxel-induced restriction of growth
and invasion of cervical cancer cells in vitro and in vivo. Ann
Transl Med. 8:11572020. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Huang H: Matrix Metalloproteinase-9
(MMP-9) as a cancer biomarker and MMP-9 biosensors: Recent
advances. Sensors (Basel). 18:32492018. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Li YJ, Liu HT, Xue CJ, Xing XQ, Dong ST,
Wang LS, Ding CY, Meng L and Dong ZJ: The synergistic anti-tumor
effect of schisandrin B and apatinib. J Asian Nat Prod Res.
22:839–849. 2020. View Article : Google Scholar
|
|
145
|
Chiu PY, Chen N, Leong PK, Leung HY and Ko
KM: Schisandrin B elicits a glutathione antioxidant response and
protects against apoptosis via the redox-sensitive ERK/Nrf2 pathway
in H9c2 cells. Mol Cell Biochem. 350:237–250. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Xu Y, Liu Z, Sun J, Pan Q, Sun F, Yan Z
and Hu X: Schisandrin B prevents doxorubicin-induced chronic
cardiotoxicity and enhances its anticancer activity in vivo. PLoS
One. 6:e283352011. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Nooreen Z, Gupta VK, Singh K, Wal A, Rai
AK and Tandon S: An updated insight on Phyto-therapeutics and their
novel approaches in the management of brain cancer. Curr Top Med
Chem. Jul 7–2025.Epub ahead of print. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Qin XL, Chen X, Zhong GP, Fan XM, Wang Y,
Xue XP, Wang Y, Huang M and Bi HC: Effect of Tacrolimus on the
pharmacokinetics of bioactive lignans of Wuzhi tablet (Schisandra
sphenanthera extract) and the potential roles of CYP3A and P-gp.
Phytomedicine. 21:766–772. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Zhan T, Yao N, Wu L, Lu Y, Liu M, Liu F,
Xiong Y and Xia C: The major effective components in Shengmai
Formula interact with sodium taurocholate co-transporting
polypeptide. Phytomedicine. 59:1529162019. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Wei JR, Lu MY, Wei TH, Fleishman JS, Yu H,
Chen XL, Kong XT, Sun SL, Li NG, Yang Y and Ni HW: Overcoming
cancer therapy resistance: From drug innovation to therapeutics.
Drug Resist Updat. 81:1012292025. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Sana-Eldine AO, Abdelgawad HM, Kotb NS and
Shehata NI: The potential effect of Schisandrin-B combination with
panitumumab in wild-type and mutant colorectal cancer cell lines:
Role of apoptosis and autophagy. J Biochem Mol Toxicol.
37:e233242023. View Article : Google Scholar
|
|
152
|
Karapetis CS, Khambata-Ford S, Jonker DJ,
O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD,
Robitaille S, et al: K-ras mutations and benefit from cetuximab in
advanced colorectal cancer. N Engl J Med. 359:1757–1765. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
153
|
De Roock W, Claes B, Bernasconi D, De
Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V,
Papamichael D, Laurent-Puig P, et al: Effects of KRAS, BRAF, NRAS,
and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy
in chemotherapy-refractory metastatic colorectal cancer: A
retrospective consortium analysis. Lancet Oncol. 11:753–762. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Van Cutsem E, Köhne CH, Láng I, Folprecht
G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D,
Tejpar S, et al: Cetuximab plus irinotecan, fluorouracil, and
leucovorin as first-line treatment for metastatic colorectal
cancer: Updated analysis of overall survival according to tumor
KRAS and BRAF mutation status. J Clin Oncol. 29:2011–2019. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Loupakis F, Pollina L, Stasi I, Ruzzo A,
Scartozzi M, Santini D, Masi G, Graziano F, Cremolini C, Rulli E,
et al: PTEN expression and KRAS mutations on primary tumors and
metastases in the prediction of benefit from cetuximab plus
irinotecan for patients with metastatic colorectal cancer. J Clin
Oncol. 27:2622–2629. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Bardelli A, Corso S, Bertotti A, Hobor S,
Valtorta E, Siravegna G, Sartore-Bianchi A, Scala E, Cassingena A,
Zecchin D, et al: Amplification of the MET receptor drives
resistance to anti-EGFR therapies in colorectal cancer. Cancer
Discov. 3:658–673. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Kavuri SM, Jain N, Galimi F, Cottino F,
Leto SM, Migliardi G, Searleman AC, Shen W, Monsey J, Trusolino L,
et al: HER2 activating mutations are targets for colorectal cancer
treatment. Cancer Discov. 5:832–841. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Maddalena F, Condelli V, Matassa DS,
Pacelli C, Scrima R, Lettini G, Li Bergolis V, Pietrafesa M, Crispo
F, Piscazzi A, et al: TRAP1 enhances Warburg metabolism through
modulation of PFK1 expression/activity and favors resistance to
EGFR inhibitors in human colorectal carcinomas. Mol Oncol.
14:3030–3047. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Yue Y, Zhang Q, Wang X and Sun Z: STAT3
regulates 5-Fu resistance in human colorectal cancer cells by
promoting Mcl-1-dependent cytoprotective autophagy. Cancer Sci.
114:2293–2305. PubMed/NCBI
|
|
160
|
Wang Y, Wang Y, Qin Z, Cai S, Yu L, Hu H
and Zeng S: The role of non-coding RNAs in ABC transporters
regulation and their clinical implications of multidrug resistance
in cancer. Expert Opin Drug Metab Toxicol. 17:291–306. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Hsu HH, Chen MC, Baskaran R, Lin YM, Day
CH, Lin YJ, Tu CC, Vijaya Padma V, Kuo WW and Huang CY: Oxaliplatin
resistance in colorectal cancer cells is mediated via activation of
ABCG2 to alleviate ER stress induced apoptosis. J Cell Physiol.
233:5458–5467. 2018. View Article : Google Scholar
|
|
162
|
Theile D and Wizgall P: Acquired
ABC-transporter overexpression in cancer cells: Transcriptional
induction or Darwinian selection? Naunyn Schmiedebergs Arch
Pharmacol. 394:1621–1632. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
163
|
Zhu Y, Huang S, Chen S, Chen J, Wang Z,
Wang Y and Zheng H: SOX2 promotes chemoresistance, cancer stem
cells properties, and epithelial-mesenchymal transition by
β-catenin and Beclin1/autophagy signaling in colorectal cancer.
Cell Death Dis. 12:4492021. View Article : Google Scholar
|
|
164
|
Kadioglu O, Law BYK, Mok SWF, Xu SW,
Efferth T and Wong VKW: Mode of action analyses of neferine, a
bisbenzylisoquinoline alkaloid of lotus (Nelumbo nucifera) against
Multidrug-resistant tumor cells. Front Pharmacol. 8:2382017.
View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Sui H, Zhou LH, Zhang YL, Huang JP, Liu X,
Ji Q, Fu XL, Wen HT, Chen ZS, Deng WL, et al: Evodiamine suppresses
ABCG2 mediated drug resistance by inhibiting p50/p65 NF-κB pathway
in colorectal cancer. J Cell Biochem. 117:1471–1481. 2016.
View Article : Google Scholar
|
|
166
|
Song B, Shuang L, Zhang S, Tong C, Chen Q,
Li Y, Hao M, Niu W and Jin CH: Research progress of nano drug
delivery systems in the anti-tumor treatment of traditional Chinese
medicine monomers. PeerJ. 13:e193322025. View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Wu J: The enhanced permeability and
retention (EPR) Effect: The significance of the concept and methods
to enhance its application. J Pers Med. 11:7712021. View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Hristova-Panusheva K, Xenodochidis C,
Georgieva M and Krasteva N: Nanoparticle-mediated drug delivery
systems for precision targeting in oncology. Pharmaceuticals
(Basel). 17:6772024. View Article : Google Scholar : PubMed/NCBI
|
|
169
|
Sun T and Jiang C: Stimuli-responsive drug
delivery systems triggered by intracellular or subcellular
microenvironments. Adv Drug Deliv Rev. 196:1147732023. View Article : Google Scholar : PubMed/NCBI
|
|
170
|
Gupta A, Costa AP, Xu X and Burgess DJ:
Continuous processing of paclitaxel polymeric micelles. Int J
Pharm. 607:1209462021. View Article : Google Scholar : PubMed/NCBI
|
|
171
|
Kara G, Calin GA and Ozpolat B: RNAi-based
therapeutics and tumor targeted delivery in cancer. Adv Drug Deliv
Rev. 182:1141132022. View Article : Google Scholar : PubMed/NCBI
|
|
172
|
Yan YH, Kong L, Lu YB, Li SY, Yan AW, Song
YW, Huang ZH and Zhu HN: Inhibition of hepatocellular carcinoma
progression by methotrexate-modified pH-sensitive sorafenib and
schisandrin B micelles. Biomed Mater. Dec 13–2024.Epud ahead of
print. PubMed/NCBI
|
|
173
|
Zhang R, Luo S, Zhao T, Wu M, Huang L,
Zhang L, Huang Y, Gao H, Sun X, Gong T and Zhang Z: Scavenger
receptor A-mediated nanoparticles target M1 macrophages for acute
liver injury. Asian J Pharm Sci. 18:1008132023.PubMed/NCBI
|
|
174
|
Di Stefano M, Galati S, Piazza L, Granchi
C, Mancini S, Fratini F, Macchia M, Poli G and Tuccinardi T:
VenomPred 2.0: A novel in silico platform for an extended and human
interpretable toxicological profiling of small molecules. J Chem
Inf Model. 64:2275–2289. 2024. View Article : Google Scholar :
|
|
175
|
Cai FY, Yao XM, Jing M, Kong L, Liu JJ, Fu
M, Liu XZ, Zhang L, He SY, Li XT and Ju RJ: Enhanced antitumour
efficacy of functionalized doxorubicin plus schisandrin B
co-delivery liposomes via inhibiting epithelial-mesenchymal
transition. J Liposome Res. 31:113–129. 2021. View Article : Google Scholar
|
|
176
|
Jing M, Bi XJ, Yao XM, Cai F, Liu JJ, Fu
M, Kong L, Liu XZ, Zhang L and He SY: Enhanced antitumor efficacy
using epirubicin and schisandrin B co-delivery liposomes modified
with PFV via inhibiting tumor metastasis. Drug Dev Ind Pharm.
46:621–634. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
177
|
Zhang L, Kong L, He SY, Liu XZ, Liu Y,
Zang J, Ju RJ and Li XT: The anti-ovarian cancer effect of RPV
modified paclitaxel plus schisandra B liposomes in SK-OV-3 cells
and tumor-bearing mice. Life Sci. 285:1200132021. View Article : Google Scholar : PubMed/NCBI
|
|
178
|
Kong L, Cai FY, Yao XM, Jing M, Fu M, Liu
JJ, He SY, Zhang L, Liu XZ, Ju RJ and Li XT: RPV-modified
epirubicin and dioscin co-delivery liposomes suppress non-small
cell lung cancer growth by limiting nutrition supply. Cancer Sci.
111:621–636. 2020. View Article : Google Scholar :
|
|
179
|
Chen RJ and Menezes RG: Vinca Alkaloid
Toxicity. StatPearls. Disclosure: Ritesh Menezes Declares no
Relevant Financial Relationships with Ineligible Companies.
StatPearls Publishing LLC; Treasure Island, FL: 2025
|
|
180
|
Li XY, Shi LX, Yao XM, Jing M, Li QQ, Wang
YL and Li QS: Functional vinorelbine plus schisandrin B liposomes
destroying tumor metastasis in treatment of gastric cancer. Drug
Dev Ind Pharm. 47:100–112. 2021. View Article : Google Scholar
|
|
181
|
Gong T, Tan T, Zhang P, Li H, Deng C,
Huang Y, Gong T and Zhang Z: Palmitic acid-modified bovine serum
albumin nanoparticles target scavenger receptor-A on activated
macrophages to treat rheumatoid arthritis. Biomaterials.
258:1202962020. View Article : Google Scholar : PubMed/NCBI
|
|
182
|
Feng J, Xiang L, Fang C, Tan Y, Li Y, Gong
T, Wu Q, Gong T and Zhang Z: Dual-targeting of tumor cells and
Tumor-associated macrophages by palmitic acid modified albumin
nanoparticles for antitumor and antimetastasis therapy. ACS Appl
Mater Interfaces. 14:14887–14902. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
183
|
Castro R, Aisenbrey E and Hui L: The role
of formulation approaches in presenting targeting ligands on lipid
nanoparticles. Nanomedicine (Lond). 18:589–597. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
184
|
Piunti C and Cimetta E: Microfluidic
approaches for producing Lipid-based nanoparticles for drug
delivery applications. Biophys Rev (Melville). 4:0313042023.
View Article : Google Scholar
|
|
185
|
Sheth P, Sandhu H, Singhal D, Malick W,
Shah N and Kislalioglu MS: Nanoparticles in the pharmaceutical
industry and the use of supercritical fluid technologies for
nanoparticle production. Curr Drug Deliv. 9:269–284. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
186
|
Sun Z, Liu Z, Han B, Miao S, Miao Z and An
G: Decoration carbon nanotubes with Pd and Ru nanocrystals via an
inorganic reaction route in supercritical carbon dioxide-methanol
solution. J Colloid Interface Sci. 304:323–328. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
187
|
Birla D, Khandale N, Bashir B, ShahbazAlam
M, Vishwas S, Gupta G, Dureja H, Kumbhar PS, Disouza J, Patravale
V, et al: Application of quality by design in optimization of
nanoformulations: Principle, perspectives and practices. Drug Deliv
Transl Res. 15:798–830. 2025. View Article : Google Scholar
|
|
188
|
Rybnikář M, Malaník M, Šmejkal K,
Švajdlenka E, Shpet P, Babica P, Dall'Acqua S, Smištík O, Jurček O
and Treml J: Dibenzocyclooctadiene Lignans from Schisandra
chinensis with Anti-Inflammatory effects. Int J Mol Sci.
25:34652024. View Article : Google Scholar
|
|
189
|
Song L, Yao L, Zhang L, Piao Z and Lu Y:
Schizandrol A protects against Aβ1-42-induced autophagy via
activation of PI3K/AKT/mTOR pathway in SH-SY5Y cells and primary
hippocampal neurons. Naunyn Schmiedebergs Arch Pharmacol.
393:1739–1752. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
190
|
Arken N: Schizandrol A reverses multidrug
resistance in resistant chronic myeloid leukemia cells K562/A02.
Cell Mol Biol (Noisy-le-Grand). 65:78–83. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
191
|
Han SJ, Jun J, Eyun SI, Lee CG, Jeon J and
Pan CH: Schisandrol A suppresses catabolic factor expression by
blocking NF-κB signaling in osteoarthritis. Pharmaceuticals
(Basel). 14:412021.
|
|
192
|
Zhou X, Zhao S, Liu T, Yao L, Zhao M, Ye
X, Zhang X, Guo Q, Tu P and Zeng K: Schisandrol A protects
AGEs-induced neuronal cells death by allosterically targeting
ATP6V0d1 subunit of V-ATPase. Acta Pharm Sin B. 12:3843–3860. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
193
|
Fong WF, Wan CK, Zhu GY, Chattopadhyay A,
Dey S, Zhao Z and Shen XL: Schisandrol A from Schisandra chinensis
reverses P-glycoprotein-mediated multidrug resistance by affecting
Pgp-substrate complexes. Planta Med. 73:212–220. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
194
|
Li L, Pan Q, Sun M, Lu Q and Hu X:
Dibenzocyclooctadiene lignans: A class of novel inhibitors of
multidrug resistance-associated protein 1. Life Sci. 80:741–748.
2007. View Article : Google Scholar
|
|
195
|
Xu G, Feng Y, Li H, Chen C, Li H, Wang C,
Chen J and Sun J: Molecular mechanism of the regulatory effect of
schisandrol a on the immune function of mice based on a
transcription factor regulatory network. Front Pharmacol.
12:7853532021. View Article : Google Scholar
|
|
196
|
Lee D, Kim YM, Chin YW and Kang KS:
Schisandrol A exhibits estrogenic activity via estrogen receptor
α-Dependent signaling pathway in estrogen Receptor-positive breast
cancer Cells. Pharmaceutics. 13:10822021. View Article : Google Scholar
|
|
197
|
Guo X, Lei M, Ma G, Ouyang C, Yang X, Liu
C, Chen Q and Liu X: Schisandrin A alleviates spatial learning and
memory impairment in diabetic rats by inhibiting inflammatory
response and through modulation of the PI3K/AKT pathway. Mol
Neurobiol. 61:2514–2529. 2024. View Article : Google Scholar
|
|
198
|
Hassanein EHM, Althagafy HS, Baraka MA,
Abd-Alhameed EK, Ibrahim IM, Abd El-Maksoud MS, Mohamed NM and Ross
SA: The promising antioxidant effects of lignans: Nrf2 activation
comes into view. Naunyn Schmiedebergs Arch Pharmacol.
397:6439–6458. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
199
|
He D, Pei X, Liu B, Li J, Dong J, Efferth
T and Ma P: Lignan contents of Schisandra chinensis (Turcz.) Baill.
from different origins-A new model for evaluating the content of
prominent components of Chinese herbs. Phytomedicine.
128:1553612024. View Article : Google Scholar : PubMed/NCBI
|
|
200
|
Li B, Zhou W, Zhang J, Wang N, Yang X and
Ge X: Schisandrin a ameliorates cardiac injury and dysfunction
induced by hemorrhagic shock via activating the Nrf2 signaling
pathway. Am J Chin Med. 52:2453–2468. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
201
|
Wang P, Lan Q, Huang Q, Zhang R, Zhang S,
Yang L, Song Y, Wang T, Ma G, Liu X, et al: Schisandrin A
attenuates diabetic nephropathy via EGFR/AKT/GSK3β signaling
pathway based on network pharmacology and experimental validation.
Biology (Basel). 13:5972024.
|
|
202
|
Xiao Y, Zhou H, Cui Y, Zhu X, Li S, Yu C,
Jiang N, Liu L and Liu F: Schisandrin A enhances pathogens
resistance by targeting a conserved p38 MAPK pathway. Int
Immunopharmacol. 128:1114722024. View Article : Google Scholar : PubMed/NCBI
|
|
203
|
Xu X, Rajamanicham V, Xu S, Liu Z, Yan T,
Liang G, Guo G, Zhou H and Wang Y: Schisandrin A inhibits triple
negative breast cancer cells by regulating Wnt/ER stress signaling
pathway. Biomed Pharmacother. 115:1089222019. View Article : Google Scholar : PubMed/NCBI
|
|
204
|
Zhu L, Wang Y, Lv W, Wu X, Sheng H, He C
and Hu J: Schizandrin A can inhibit non-small cell lung cancer cell
proliferation by inducing cell cycle arrest, apoptosis and
autophagy. Int J Mol Med. 48:2142021. View Article : Google Scholar :
|
|
205
|
Chi B, Sun Y, Zhao J and Guo Y:
Deoxyschizandrin inhibits the proliferation, migration, and
invasion of bladder cancer cells through ALOX5 regulating PI3K-AKT
signaling pathway. J Immunol Res. 2022:30798232022. View Article : Google Scholar : PubMed/NCBI
|
|
206
|
He LW, Lin CJ, Zhuang LJ, Sun YH, Li YC
and Ye ZY: Targeting hepatocellular carcinoma: Schisandrin A
triggers mitochondrial disruption and ferroptosis. Chem Biol Drug
Des. 104:e700102024. View Article : Google Scholar : PubMed/NCBI
|
|
207
|
Peng CW, Ma PL and Dai HT: Schizandrin A
promotes apoptosis in prostate cancer by inducing ROS-mediated
endoplasmic reticulum stress and JNK MAPK signaling activation.
Pathol Res Pract. 269:1558892025. View Article : Google Scholar : PubMed/NCBI
|
|
208
|
Ding Y, Guo N, Jiang Y, Liu S, Zhou T, Bai
H, Lv Y, Han S and He L: Establishment of cluster of
differentiation 20 immobilized cell membrane chromatography for the
screening of active antitumor components in traditional Chinese
medicine. J Chromatogr A. 1721:4648452024. View Article : Google Scholar : PubMed/NCBI
|
|
209
|
Zhang ZL, Jiang QC and Wang SR:
Schisandrin A reverses doxorubicin-resistant human breast cancer
cell line by the inhibition of P65 and Stat3 phosphorylation.
Breast Cancer. 25:233–242. 2018. View Article : Google Scholar
|
|
210
|
Xian H, Feng W and Zhang J: Schizandrin A
enhances the efficacy of gefitinib by suppressing IKKβ/NF-κB
signaling in non-small cell lung cancer. Eur J Pharmacol.
855:10–19. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
211
|
Zheng A, Yang D, Pan C, He Q, Zhu X, Xiang
X and Ji P: Modeling the complexity of drug-drug interactions: A
physiologically-based pharmacokinetic study of Lenvatinib with
Schisantherin A/Schisandrin A. Eur J Pharm Sci. 196:1067572024.
View Article : Google Scholar : PubMed/NCBI
|
|
212
|
Wang X, Wang F, Dong P and Zhou L: The
therapeutic effect of ultrasound targeted destruction of
schisandrin A contrast microbubbles on liver cancer and its
mechanism. Radiol Oncol. 58:221–233. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
213
|
Xu SY, Wang WW, Qu ZH, Zhang XK, Chen M,
Zhang XY, Xing NN, Su H, Wang XY, Cui MY, et al: Long-circulating
doxorubicin and Schizandrin A liposome with Drug-resistant liver
cancer activity: In vitro and in vivo evaluation. J Liposome Res.
33:338–352. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
214
|
Kim JS and Yi HK: Schisandrin C enhances
mitochondrial biogenesis and autophagy in C2C12 skeletal muscle
cells: Potential involvement of anti-oxidative mechanisms. Naunyn
Schmiedebergs Arch Pharmacol. 391:197–206. 2018. View Article : Google Scholar
|
|
215
|
Takanche JS, Lee YH, Kim JS, Kim JE, Han
SH, Lee SW and Yi HK: Anti-inflammatory and antioxidant properties
of Schisandrin C promote mitochondrial biogenesis in human dental
pulp cells. Int Endod J. 51:438–447. 2018. View Article : Google Scholar
|
|
216
|
Yan H, Wu W, Hu Y, Li J, Xu J, Chen X, Xu
Z, Yang X, Yang B, He Q and Luo P: Regorafenib inhibits EphA2
phosphorylation and leads to liver damage via the ERK/MDM2/p53
axis. Nat Commun. 14:27562023. View Article : Google Scholar : PubMed/NCBI
|
|
217
|
Xu B, Liu N, Zhou T, Chen J, Jiang L, Wu
W, Fu H, Chen X, Yan H, Yang X, et al: Schisandrin C prevents
regorafenib-induced cardiotoxicity by recovering EPHA2 expression
in cardiomyocytes. Toxicol Sci. 202:220–235. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
218
|
Park C, Choi YW, Hyun SK, Kwon HJ, Hwang
HJ, Kim GY, Choi BT, Kim BW, Choi IW, Moon SK, et al: Induction of
G1 arrest and apoptosis by schisandrin C isolated from Schizandra
chinensis Baill in human leukemia U937 cells. Int J Mol Med.
24:495–502. 2009.PubMed/NCBI
|
|
219
|
Wang Z, Xie S, Li L, Liu Z and Zhou W:
Schisandrin C inhibits AKT1-regulated cell proliferation in A549
cells. Int Immunopharmacol. 142:1131102024. View Article : Google Scholar : PubMed/NCBI
|
|
220
|
Samson N and Ablasser A: The cGAS-STING
pathway and cancer. Nat Cancer. 3:1452–1463. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
221
|
Yang H, Zhan X, Zhao J, Shi W, Liu T, Wei
Z, Li H, Hou X, Mu W, Chen Y, et al: Schisandrin C enhances type I
IFN response activation to reduce tumor growth and sensitize
chemotherapy through antitumor immunity. Front Pharmacol.
15:13695632024. View Article : Google Scholar : PubMed/NCBI
|
|
222
|
Wu Z, Zhao X, Li R, Wen X, Xiu Y, Long M,
Li J, Huang X, Wen J, Dong X, et al: The combination of Schisandrin
C and Luteolin synergistically attenuates hepatitis B virus
infection via repressing HBV replication and promoting cGAS-STING
pathway activation in macrophages. Chin Med. 19:482024. View Article : Google Scholar : PubMed/NCBI
|
|
223
|
Liu HW, Yu XZ, Padula D, Pescitelli G, Lin
ZW, Wang F, Ding K, Lei M and Gao JM: Lignans from Schisandra
sphenathera Rehd. et Wils. and semisynthetic schisantherin A
analogues: Absolute configuration, and their estrogenic and
Anti-proliferative activity. Eur J Med Chem. 59:265–273. 2013.
View Article : Google Scholar
|
|
224
|
Wang Z, Yu K, Hu Y, Su F, Gao Z, Hu T,
Yang Y, Cao X and Qian F: Schisantherin A induces cell apoptosis
through ROS/JNK signaling pathway in human gastric cancer cells.
Biochem Pharmacol. 173:1136732020. View Article : Google Scholar
|
|
225
|
Feng F, Pan L, Wu J, Liu M, He L, Yang L
and Zhou W: Schisantherin A inhibits cell proliferation by
regulating glucose metabolism pathway in hepatocellular carcinoma.
Front Pharmacol. 13:10194862022. View Article : Google Scholar : PubMed/NCBI
|
|
226
|
Chen L, Ji N, Zhang M and Chen W: The
influence of wuzhi capsule on the pharmacokinetics of
cyclophosphamide. Recent Pat Anticancer Drug Discov. 17:195–203.
2022. View Article : Google Scholar
|
|
227
|
Adiwidjaja J, Boddy AV and McLachlan AJ:
Potential for pharmacokinetic interactions between Schisandra
sphenanthera and bosutinib, but not imatinib: In vitro metabolism
study combined with a physiologically-based pharmacokinetic
modelling approach. Br J Clin Pharmacol. 86:2080–2094. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
228
|
Kudo M, Finn RS, Qin S, Han KH, Ikeda K,
Piscaglia F, Baron A, Park JW, Han G and Jassem J: Lenvatinib
versus sorafenib in first-line treatment of patients with
unresectable hepatocellular carcinoma: A randomised phase 3
non-inferiority trial. Lancet. 391:1163–1173. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
229
|
Cui Y, Ma Y, Li Y, Song H and Dong Z:
Influence of schisantherin A on the pharmacokinetics of lenvatinib
in rats and its potential mechanism. J Gastrointest Oncol.
13:802–811. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
230
|
Sobstyl E, Szopa A, Dziurka M, Ekiert H,
Nikolaichuk H and Choma IM: Schisandra rubriflora fruit and leaves
as promising new materials of high biological potential: Lignan
profiling and Effect-directed analysis. Molecules. 27:21162022.
View Article : Google Scholar : PubMed/NCBI
|
|
231
|
Deng L, Cheng S, Li J, Xu X, Hao X, Fan Y
and Mu S: Synthesis and biological evaluation of novel schisanhenol
derivatives as potential hepatoprotective agents. Eur J Med Chem.
227:1139192022. View Article : Google Scholar
|
|
232
|
Li B, Xiao Q, Zhao H, Zhang J, Yang C, Zou
Y, Zhang B, Liu J, Sun H and Liu H: Schisanhenol ameliorates
Non-alcoholic fatty liver disease via inhibiting miR-802 activation
of AMPK-mediated modulation of hepatic lipid metabolism. Acta Pharm
Sin B. 14:3949–3963. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
233
|
He X, Chen J, Mu Y, Zhang H, Chen G, Liu P
and Liu W: The effects of inhibiting the activation of hepatic
stellate cells by lignan components from the fruits of Schisandra
chinensis and the mechanism of schisanhenol. J Nat Med. 74:513–524.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
234
|
Zhang Z, Zhong Y, Han X, Hu X, Wang Y,
Huang L, Li S, Li Z, Wang C, Li H, et al: Schisanhenol inhibits the
proliferation of hepatocellular carcinoma cells by targeting
programmed cell Death-ligand 1 via the STAT3 pathways. Anticancer
Agents Med Chem. 25:697–710. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
235
|
Jeong M, Kim HM, Kim HJ, Choi JH and Jang
DS: Kudsuphilactone B, a nortriterpenoid isolated from Schisandra
chinensis fruit, induces caspase-dependent apoptosis in human
ovarian cancer A2780 cells. Arch Pharm Res. 40:500–508. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
236
|
Liu M, Yang K and Qiu H: Exploring the
effect of gomisin A on non-small cell lung cancer with network
pharmacology, molecular docking, in vitro and in vivo assays. Chem
Biol Drug Des. 104:e700142024. View Article : Google Scholar
|
|
237
|
Wang T, Liu J, Huang X, Zhang C, Shangguan
M, Chen J, Wu S, Chen M, Yang Z and Zhao S: Gomisin A enhances the
antitumor effect of paclitaxel by suppressing oxidative stress in
ovarian cancer. Oncol Rep. 48:2022022. View Article : Google Scholar : PubMed/NCBI
|
|
238
|
Kee JY, Han YH, Mun JG, Park SH, Jeon HD
and Hong SH: Gomisin A suppresses colorectal lung metastasis by
inducing AMPK/p38-mediated apoptosis and decreasing metastatic
abilities of colorectal cancer cells. Front Pharmacol. 9:9862018.
View Article : Google Scholar : PubMed/NCBI
|
|
239
|
Han YH, Mun JG, Jeon HD, Park J, Kee JY
and Hong SH: Gomisin A ameliorates metastatic melanoma by
inhibiting AMPK and ERK/JNK-mediated cell survival and metastatic
phenotypes. Phytomedicine. 68:1531472020. View Article : Google Scholar : PubMed/NCBI
|
|
240
|
Wang R, Liu F, Chen P, Li S, Gu Y, Wang L,
Chen C and Yuan Y: Gomisin D alleviates liver fibrosis through
targeting PDGFRβ in hepatic stellate cells. Int J Biol Macromol.
235:1236392023. View Article : Google Scholar
|
|
241
|
Jeon JS, Kang HM, Park SY and Choi YW:
Comparative study of the photo-protective and anti-melanogenic
properties of gomisin D, J and O. Mol Med Rep. 25:82022. View Article : Google Scholar
|
|
242
|
Maharjan S, Park BK, Lee SI, Lim Y, Lee K,
Lee Y and Kwon HJ: Gomisin G Suppresses the Growth of colon cancer
cells by attenuation of AKT phosphorylation and arrest of cell
cycle progression. Biomol Ther (Seoul). 27:210–215. 2019.
View Article : Google Scholar
|
|
243
|
Maharjan S, Park BK, Lee SI, Lim Y, Lee K
and Kwon HJ: Gomisin G inhibits the growth of triple-Negative
breast cancer cells by suppressing AKT phosphorylation and
decreasing cyclin D1. Biomol Ther (Seoul). 26:322–327. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
244
|
Yeon M, Choi H, Chun KH, Lee JH and Jun
HS: Gomisin G improves muscle strength by enhancing mitochondrial
biogenesis and function in disuse muscle atrophic mice. Biomed
Pharmacother. 153:1134062022. View Article : Google Scholar : PubMed/NCBI
|
|
245
|
Mokhtari T and El-Meghawry El-Kenawy A:
Molecular mechanisms of Schisandra chinensis in treating
depression-neuropathic pain comorbidity by network pharmacology and
molecular docking analysis. Neuroscience. 555:92–105. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
246
|
Jung S, Moon HI, Kim S, Quynh NTN, Yu J,
Sandag Z, Le DT, Lee H, Lee H and Lee MS: Anticancer activity of
gomisin J from Schisandra chinensis fruit. Oncol Rep. 41:711–717.
2019.
|
|
247
|
Kang K, Lee KM, Yoo JH, Lee HJ, Kim CY and
Nho CW: Dibenzocyclooctadiene lignans, gomisins J and N inhibit the
Wnt/β-catenin signaling pathway in HCT116 cells. Biochem Biophys
Res Commun. 428:285–291. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
248
|
Li R and Yang W: Gomisin J inhibits the
glioma progression by inducing apoptosis and reducing
HKII-regulated glycolysis. Biochem Biophys Res Commun. 529:15–22.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
249
|
He XR, Han SY, Li XH, Zheng WX, Pang LN,
Jiang ST and Li PP: Chinese medicine Bu-Fei decoction attenuates
epithelial-mesenchymal transition of Non-small cell lung cancer via
inhibition of transforming growth factor β1 signaling pathway in
vitro and in vivo. J Ethnopharmacol. 204:45–57. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
250
|
Garcia-Aguilar J, Patil S, Gollub MJ, Kim
JK, Yuval JB, Thompson HM, Verheij FS, Omer DM, Lee M, Dunne RF, et
al: Organ preservation in patients with rectal adenocarcinoma
treated with total neoadjuvant therapy. J Clin Oncol. 40:2546–2556.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
251
|
Schaff LR and Mellinghoff IK: Glioblastoma
and other primary brain malignancies in adults: A review. JAMA.
329:574–587. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
252
|
Moris D, Palta M, Kim C, Allen PJ, Morse
MA and Lidsky ME: Advances in the treatment of intrahepatic
cholangiocarcinoma: An overview of the current and future
therapeutic landscape for clinicians. CA Cancer J Clin. 73:198–222.
2023.
|
|
253
|
Kim SM, Vetrivel P, Ha SE, Kim HH, Kim JA
and Kim GS: Apigetrin induces extrinsic apoptosis, autophagy and
G2/M phase cell cycle arrest through PI3K/AKT/mTOR pathway in AGS
human gastric cancer cell. J Nutr Biochem. 83:1084272020.
View Article : Google Scholar : PubMed/NCBI
|
|
254
|
Wu YF, Cao MF, Gao YP, Chen F, Wang T,
Zumbika EP and Qian KX: Down-modulation of heat shock protein 70
and up-modulation of Caspase-3 during schisandrin B-induced
apoptosis in human hepatoma SMMC-7721 cells. World J Gastroenterol.
10:2944–2948. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
255
|
Raychaudhuri R, Lin DW and Montgomery RB:
Prostate cancer: A review. JAMA. 333:1433–1446. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
256
|
Wang Y, Chen J, Huang Y, Yang S, Tan T,
Wang N, Zhang J, Ye C, Wei M, Luo J and Luo X: Schisandrin B
suppresses osteosarcoma lung metastasis in vivo by inhibiting the
activation of the Wnt/β-catenin and PI3K/Akt signaling pathways.
Oncol Rep. 47:502022. View Article : Google Scholar
|
|
257
|
Maharjan S, Park BK, Lee SI, Lim Y, Lee K
and Kwon HJ: Erratum to 'Gomisin G Inhibits the Growth of
Triple-Negative Breast Cancer Cells by Suppressing AKT
Phosphorylation and Decreasing Cyclin D1' [Biomol.Ther. 26 (2018)
322-327]. Biomol Ther (Seoul). 26:5202018. View Article : Google Scholar
|
